

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
12 May 2022 (12.05.2022)



(10) International Publication Number
WO 2022/098914 A1

(51) International Patent Classification:

C12N 5/0783 (2010.01) C07K 14/715 (2006.01)
C07K 14/705 (2006.01) A61K 35/17 (2014.01)

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(21) International Application Number:

PCT/US2021/058118

(22) International Filing Date:

04 November 2021 (04.11.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/109,828 04 November 2020 (04.11.2020) US

(71) Applicant: **FATE THERAPEUTICS, INC.** [US/US];
12278 Scripps Summit Drive, San Diego, CA 92131 (US).

(72) Inventors: **VALAMEHR, Bahram**; 12278 Scripps Summit Drive, San Diego, CA 92131 (US). **PERALTA, Eigen**; 12278 Scripps Summit Drive, San Diego, CA 92131 (US). **CHANG, Chia-Wei**; 12278 Scripps Summit Drive, San Diego, CA 92131 (US).

(74) Agent: **GIERING, Jeffery C.** et al.; Greenberg Traurig, LLP, 18565 Jamboree Road, Suite 500, Irvine, CA 92612 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: ENGINEERED IPSC AND PERSISTENT IMMUNE EFFECTOR CELLS

(57) Abstract: Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. The iPSC-derived cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.



WO 2022/098914 A1